Kodiak Sciences Inc. (KOD)
KODNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$107.15
+0.0496 (+0.05%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $107.80 +0.65%
- Market cap
- $6.78bn
- P/E
- –
- EPS, last 4 quarters
- $-4.19
- Dividend yield
- –
- Day range
- –
- 52-week range
- $18.05 to $107.53
- Average volume
- 2.03m
- Previous close
- $107.10
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $121.20, +13.1% from here
Earnings
next estimate $-1.00Next report Nov 12, 2026
Sep 2025
-8.4%
Dec 2025
-2.0%
Mar 2026
-1.1%
Jun 2026
-8.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$62.35m | -$57.45m | -$59.78m | -$66.84m |
| Net income | -$61.46m | -$56.74m | -$58.16m | -$65.64m |
News
8 latest- Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?Zacks · Oct 19, 2026
- Kodiak Sciences Consensus Price Target Increased by 65.16% to $117.50Fintel · Oct 2, 2026
- Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III StudyMarketBeat · Oct 2, 2026
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data RTTNews · Oct 2, 2026
- Show Me The Money: Kodiak Sciences Shares Deliver More Than 500% Return In Just Over A Year RTTNews · Oct 2, 2026
- Biotech Stocks At 52-Week Highs - KOD, MASS, OBIO, CDNA, PMVP RTTNews · Oct 2, 2026
- Stocks Settle Lower on Rising Bond YieldsBarchart · Sep 29, 2026
- KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsZacks · Sep 29, 2026
The company
Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- kodiak.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.